Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Isaac Gannon
Institutions:
University College Hospital,
University College London Hospitals NHS Foundation Trust,
University College London
Observed institutions:
University College Hospital,
University College London Hospitals NHS Foundation Trust,
Autolus (United Kingdom),
University College London
ORCID:
0000-0002-5821-2642
Observed ORCID:
0000-0002-5821-2642
OpenAlex ID:
A5012690234
Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR
2023
·
Evangelia Kokalaki
, Biao Ma
, et al.
·
Molecular Therapy
·
45
PDF
Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies
2024
·
Mathieu Ferrari
, Matteo Righi
, et al.
·
Nature Communications
·
26
PDF
Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment
2024
·
Alexandros Rampotas
, Zoe Wong
, et al.
·
Blood
·
17
Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors
2023
·
Matteo Righi
, Isaac Gannon
, et al.
·
Cancer Immunology Research
·
15
PDF
Designer Small-Molecule Control System Based on Minocycline-Induced Disruption of Protein–Protein Interaction
2024
·
Ram Jha
, Alexander Kinna
, et al.
·
ACS Chemical Biology
·
9
Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2
2023
·
Julia Taylor
, Anna Bulek
, et al.
·
Frontiers in Immunology
·
9
PDF
CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis
2026
·
Alexandros Rampotas
, Zoë C. Wong
, et al.
·
Science Translational Medicine
·
6
Immunotherapies for Breast Cancer: From Checkpoint Inhibition to Emerging Cellular Therapies
2026
·
Ismini Tsagkaraki
, Isaac Gannon
, et al.
·
Cancers
·
6
PDF
Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR
2023
·
Evangelia Kokalaki
, Biao Ma
, et al.
·
Molecular Therapy
·
2
CAR cellular therapies for acute myeloid leukemia: current landscape and future directions
2026
·
Jure Hederih
, James Patrick
, et al.
·
Immunotherapy
·
1
To c or not to c-KIT?: High toxicity and modest efficacy in CD117-directed CAR T cell therapy
2025
·
Isaac Gannon
, Claire Roddie
, et al.
·
Molecular Therapy
·
1
Choosing the right double-barreled gun: ARI0003 takes aim at lymphoma by targeting both CD19 and BCMA
2024
·
Alexandros Rampotas
, Isaac Gannon
, et al.
·
Molecular Therapy
·
1
Abstract C049: Implementing human bone marrow organoids to interrogate microenvironmental influences on the efficacy of blood cancer immunotherapies
2024
·
Zoë C. Wong
, Yuqi Shen
, et al.
·
Cancer Research
·
1
How could calreticulin-targeting therapies change the myelofibrosis transplant paradigm?
2026
·
Amy MacDonald
, Isaac Gannon
, et al.
·
Bone Marrow Transplantation
PDF
Outcomes for post‐transplant relapsed acute lymphoblastic leukaemia in the era of novel therapies: A retrospective multicentre UK study
2026
·
Alexandros Rampotas
, Amy A. Kirkwood
, et al.
·
British Journal of Haematology
Supplementary Table 1 from Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors
2025
·
Matteo Righi
, Isaac Gannon
, et al.
PDF
Supplementary Table 2 from Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors
2025
·
Matteo Righi
, Isaac Gannon
, et al.
PDF
Supplementary Figure S1-S26 from Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors
2025
·
Matteo Righi
, Isaac Gannon
, et al.
PDF
Data from Enhancing CAR T-cell therapy using Fab-Based Constitutively Heterodimeric Cytokine Receptors
2024
·
Matteo Righi
, Isaac Gannon
, et al.
Supplementary Figure S1-S26 from Enhancing CAR T-cell therapy using Fab-Based Constitutively Heterodimeric Cytokine Receptors
2024
·
Matteo Righi
, Isaac Gannon
, et al.
Supplementary Figure S1-S26 from Enhancing CAR T-cell therapy using Fab-Based Constitutively Heterodimeric Cytokine Receptors
2024
·
Matteo Righi
, Isaac Gannon
, et al.
Supplementary Table 1 from Enhancing CAR T-cell therapy using Fab-Based Constitutively Heterodimeric Cytokine Receptors
2024
·
Matteo Righi
, Isaac Gannon
, et al.
Supplementary Table 2 from Enhancing CAR T-cell therapy using Fab-Based Constitutively Heterodimeric Cytokine Receptors
2024
·
Matteo Righi
, Isaac Gannon
, et al.
Supplementary Table 1 from Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors
2023
·
Matteo Righi
, Isaac Gannon
, et al.
PDF
Supplementary Table 2 from Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors
2023
·
Matteo Righi
, Isaac Gannon
, et al.
PDF
Show more works
View as search
Works count:
32
Citation count:
139
H-index:
6
I10-index:
4
Year
Topic
Type